August 17, 2026
There is a telling gap in the MedTech sector right now. On one side, the NHS has undergone one of the most significant structural transformations in its history. On the other, many MedTech companies are still hiring, training, and deploying commercial teams built for the procurement environment of five years ago.
The consequences are beginning to show. Sales cycles are lengthening. Approval rates through NICE are not automatically translating into adoption. Field-based reps with strong clinical relationships are finding that relationships alone are no longer enough to move a decision forward.
This is not a market access problem. It is a commercial talent problem — and it needs to be addressed before 2028.
To understand the hiring problem, you first need to understand what the NHS looks like commercially in 2026.
In 2022, 42 Integrated Care Boards (ICBs) replaced Clinical Commissioning Groups across England. These are not simply renamed versions of the same structure. ICBs operate as statutory bodies responsible for planning and commissioning health services for defined populations, and they work within a broader Integrated Care System (ICS) that brings together NHS providers, local authorities, and other partners around population-level health outcomes.
This shift has moved procurement authority decisively upward and outward. Decisions that previously sat with department heads, surgeons, or clinical leads at trust level are now shaped at ICB and ICS level, where the questions being asked are fundamentally different. The conversation is no longer primarily about product efficacy at the point of care. It is about pathway integration, population-level impact, budget sustainability, and how a given technology fits within a multi-year commissioning strategy.
According to analysis of NHS commercial engagement patterns, successful engagement with ICBs now requires building relationships with Directors of Strategy, Population Health Leads, and Primary Care Transformation Teams — not just procurement contacts or clinical champions within a single department. The average hospital purchasing decision now involves between six and ten stakeholders. A commercial professional who knows the right surgeon but cannot navigate an ICB committee is operating with a significant structural disadvantage.
In June 2026, the NHS officially rolled out a value-based procurement (VBP) methodology across England — the culmination of more than three years of development and piloting. The implications for MedTech commercial strategy are material.
Under VBP, cost is capped at 40% of procurement scores. The remaining 60% or more is weighted toward broader value measures: patient outcomes, patient experience, and environmental impact. This is a codified, system-wide shift from price-based purchasing toward evidence-based value purchasing. A MedTech commercial professional who leads with cost or volume arguments is now structurally disadvantaged in the procurement process — not merely unfashionable, but algorithmically deprioritised.
From April 2026, NICE increased its cost-effectiveness thresholds from the previous range of £20,000–£30,000 per QALY to £25,000–£35,000 per QALY. This creates resubmission opportunities for previously marginal technologies and signals a more receptive environment for innovative MedTech products.
However, a NICE positive recommendation alone still does not guarantee NHS adoption. The MedTech Funding Mandate (MTFM), which requires products to demonstrate net cost savings within three years and a budget impact below £20 million, supported only one technology in 2025/26. The National HealthTech Access Programme (NHAP), which creates legal funding obligations for selected technologies, is deliberately targeted at a small number of high-impact priorities.
For the vast majority of MedTech companies, commercial teams still need to convert NICE recommendations into actual commissioning decisions at ICB and trust level — with no automatic funding mechanism to rely on. This is precisely where the capability gap is most acute.
The NHS 10 Year Plan commits to the rapid adoption of innovative MedTech, wearables, digital tools, and AI across the health system, with "best value and outcomes" explicitly replacing lowest cost as the procurement philosophy. A new national internal marketplace for productivity-enhancing products has been signalled, alongside accelerated commercial support and simplified evidence generation pathways. The direction is clear: the NHS wants to adopt innovation, but on its terms, and through evidence-based commercial relationships.
Despite these structural changes, the default hiring specification for a MedTech commercial role in the UK NHS still looks remarkably similar to what it did five years ago. Strong clinical background. Established relationships in a given therapy area. Track record of hitting revenue targets. Territory management experience.
These are not worthless attributes. But they describe a role that was designed for a procurement environment that no longer exists in the same form.
The traditional field sales model was built on three assumptions: that the primary decision-maker was a clinical specialist, that product demonstration and peer-to-peer clinical conversation were the primary conversion tools, and that centralised negotiation happened only above a certain deal threshold. All three assumptions have been eroded.
The problem is compounded by a talent pipeline that has not kept pace. Commercial teams being built today often reflect the hiring criteria, career pathways, and competency frameworks of the previous decade. Candidates are assessed on therapy area knowledge and relationship networks — both genuinely valuable — but rarely on their ability to construct a health economic argument, read an ICB population health strategy, or engage credibly with a Transformation Director about pathway redesign.
Heading into 2028, the competency profile of a high-performing NHS MedTech commercial professional is not simply an evolved version of the traditional field rep. It is a qualitatively different role.
Deep clinical understanding of a therapy area is still necessary. But in the context of VBP, NICE evaluation, and ICS-level commissioning, clinical credibility alone is insufficient. The commercial professional of 2028 must be able to translate clinical evidence into economic and system-level value propositions — and do so in front of audiences that include finance leads, ICB strategy directors, and procurement professionals who may not have a clinical background.
The ability to construct and communicate health economic arguments — cost per episode, pathway cost modelling, budget impact analysis, quality-adjusted outcomes — has become a core commercial competency. Under value-based procurement, where 60% or more of a procurement score is weighted on non-cost value factors, commercial professionals who cannot articulate a credible economic case are not just less effective: they are leaving quantifiable score points on the table.
This does not mean every commercial hire needs a health economics degree. It means the functional understanding of how NHS financial decision-makers evaluate proposals must be built into commercial training, hiring criteria, and team composition.
Territory management has evolved into system account management. The commercial professional working in the NHS in 2028 needs to understand the strategy of the ICB they are operating within — its published population health priorities, its transformation programmes, its integration with social care and primary care — and position their company as a partner in that strategy rather than a vendor responding to procurement cycles.
This requires stakeholder mapping skills, multi-year account planning capability, and the ability to engage at executive level with NHS leadership — skills typically associated with key account management in pharma or strategic consulting, not traditional MedTech field sales.
One of the most significant shifts underway is the blurring of the boundary between clinical affairs, medical affairs, and commercial. As real-world evidence becomes a procurement requirement rather than a regulatory nicety, commercial professionals need to understand how evidence is generated, how it is presented in NICE submissions, and how it maps to ICB commissioning criteria.
The best commercial teams in 2028 will have strong internal bridges between medical affairs and commercial, and individual commercial professionals will be expected to understand — and credibly discuss — the evidence underpinning their company's NHS proposition.
The gap between where commercial hiring currently sits and where it needs to be represents both a risk and an opportunity.
Companies that continue to recruit for the 2020 commercial model will find that strong individuals underperform in the 2026 environment — not because they lack capability, but because their capability set does not match the environment they are being asked to work in. The NHS is not coming back to a simpler procurement model. The VBP rollout, the NICE reforms, the ICS structure, and the 10 Year Plan all point in the same direction.
The opportunity is for organisations willing to redefine what commercial excellence looks like in the NHS context. That means updating job specifications and competency frameworks, investing in health economics training for commercial teams, hiring from adjacent talent pools — clinical affairs, medical science liaison, NHS consulting — and restructuring team models to reflect the complexity of ICS-level engagement.
The companies that get this right in the next two years will be structurally better positioned heading into 2028. Those that do not will find that even high-quality products, with NICE approval and strong clinical evidence, struggle to convert that into NHS adoption — not because of the product, but because of the commercial model.
The NHS has not simply changed its procurement processes. It has changed the fundamental nature of what a high-value commercial relationship looks like. The ICS model, value-based procurement, NICE's evolving evidence requirements, and the NHS 10 Year Plan's commitment to outcomes-based purchasing have collectively created an environment where the traditional MedTech field sales model is no longer sufficient.
The commercial professional who thrives in this environment is not a product specialist with good relationships. They are part clinical communicator, part health economist, part system strategist. Building a team with those capabilities — and hiring for them deliberately — is not a future consideration. For organisations with NHS-facing commercial ambitions heading into 2028, it is the work of right now.
CTA: At 44 International, we specialise in placing senior commercial talent across the MedTech and Life Sciences sectors. If you are assessing the capabilities of your NHS commercial team — or building one for the next phase of your UK market strategy — speak with one of our consultants. We help organisations identify, attract, and retain the commercial leaders that the 2028 NHS environment demands.
Why This Topic Matters Now:
The convergence of several simultaneous changes makes this topic directly relevant to NHS-facing MedTech companies in mid-2026:
The topic sits at the intersection of NHS system reform, MedTech commercial strategy, and specialist talent acquisition — making it directly relevant to the thought leadership positioning of 44 International across all three.
© All rights reserved